Cryoport, Inc. (NASDAQ:CYRX) Shares Purchased by Millennium Management LLC

Millennium Management LLC increased its stake in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 11.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,139,869 shares of the company's stock after purchasing an additional 409,353 shares during the quarter. Millennium Management LLC owned 8.38% of Cryoport worth $32,208,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Cadian Capital Management LP raised its stake in Cryoport by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock worth $38,332,000 after acquiring an additional 609,021 shares in the last quarter. Deutsche Bank AG increased its position in Cryoport by 0.9% in the 4th quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock valued at $10,870,000 after acquiring an additional 12,864 shares during the period. Dimensional Fund Advisors LP increased its position in Cryoport by 8.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock valued at $6,615,000 after acquiring an additional 63,301 shares during the period. LPL Financial LLC raised its stake in shares of Cryoport by 1,366.1% during the 4th quarter. LPL Financial LLC now owns 436,766 shares of the company's stock worth $3,398,000 after buying an additional 406,976 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Cryoport by 20.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 408,385 shares of the company's stock worth $3,177,000 after buying an additional 68,474 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CYRX shares. Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a report on Thursday, May 8th. Guggenheim restated a "buy" rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Roth Mkm reiterated a "buy" rating and set a $15.00 target price on shares of Cryoport in a report on Tuesday, April 1st. UBS Group increased their target price on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Finally, Morgan Stanley lowered their target price on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $11.00.

Insider Activity at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 19,830 shares of company stock worth $118,353. 10.00% of the stock is owned by insiders.

Cryoport Trading Down 2.9%

NASDAQ:CYRX traded down $0.18 during mid-day trading on Friday, reaching $6.04. The company's stock had a trading volume of 253,099 shares, compared to its average volume of 543,684. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $11.64. The company's fifty day simple moving average is $5.93 and its two-hundred day simple moving average is $6.82. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The stock has a market cap of $302.83 million, a P/E ratio of -1.79 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. On average, equities analysts predict that Cryoport, Inc. will post -0.99 EPS for the current year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.